The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference on January 12, 2012

Thursday, December 29, 2011

Questcor Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference on January 12, 201206:30 EST Thursday, December 29, 2011ANAHEIM, Calif., Dec. 29, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the 30th Annual J.P. Morgan Healthcare Conference on January 12, 2012 to be held on January 9-12, 2012 in San Francisco.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Thursday, January 12, 2012 at 10:00 a.m. ET.  A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.About Questcor                                                                                      Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.    SOURCE Questcor Pharmaceuticals, Inc.For further information: Questcor Pharmaceuticals, Inc., Don Bailey, +1-714-786-4210, dbailey@Questcor.com; or EVC Group, Investors, Gregory Gin, +1-646-445-4801, or Doug Sherk, +1-415-568-4887, or Media, Janine McCargo, +1-646-688-0425